Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p-coumaric acid is a naturally occurring phenolic acid and a hydroxycinnamic acid derivative with potent anti-inflammatory and anti-fibrotic properties. It has been identified as a novel therapeutic candidate for hyperuricemic nephropathy (HN) due to its ability to directly bind to and inhibit the enzymatic activity of the lysosomal cysteine protease Cathepsin B (CTSB). By altering the spatial conformation of CTSB, p-coumaric acid prevents the protease from interacting with NLRP3 in the cytosol, thereby suppressing the activation of the NLRP3-ASC-caspase-1-GSDMD-N-IL-18/IL-1β signaling cascade. This mechanism effectively attenuates tubulointerstitial inflammation and renal fibrosis in disease models. Beyond its potential as a pharmaceutical lead, p-coumaric acid is widely found in dietary sources such as fruits, vegetables, and cereals, and is recognized for its antioxidant and nutraceutical benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on p-coumaric acid.